HopeStage
Back to all studies
CompletedNCT06360419

Solriamfetol study of brain chemicals and depression

About this titleRead the official source — NCT06360419

Researchers compared Solriamfetol 300 mg and placebo to find out how the approaches affected depression symptoms in people with depression.

Medication studyAges 18–65United States
The study in practice

Understand this study

What did researchers investigate?

Researchers compared Solriamfetol 300 mg and placebo to find out how the approaches affected depression symptoms in people with depression.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Little Rock and 39 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: March 18, 2024
Recruitment status
Completed
Enrollment listed in the registry
346
Sponsor
Axsome Therapeutics, Inc.
Sponsor type
Biotech company
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT06360419
Official title
Show the full official title

A Randomized, Double-Blind, Placebo-Controlled Trial of Solriamfetol in Subjects With Major Depressive Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Little Rock · Bellflower · Encino

35 more locations
  • Lemon Grove
  • Los Angeles
  • Montclair
  • Oceanside
  • Redlands
  • Riverside
  • Sherman Oaks
  • Torrance
  • Upland
  • Walnut Creek
  • Cromwell
  • Brandon
  • Hialeah
  • Jacksonville
  • Orlando
  • Chicago
  • Overland Park
  • New Orleans
  • Boston
  • Saint Charles
  • Las Vegas
  • Brooklyn
  • Rochester
  • Staten Island
  • Hickory
  • Cincinnati
  • Oklahoma City
  • Media
  • Philadelphia
  • Memphis
  • Austin
  • Dallas
  • Friendswood
  • Wichita Falls
  • Everett

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

Researchers compared Solriamfetol 300 mg and placebo to find out how the approaches affected depression symptoms in people with depression.

Who is behind this study?

The study sponsor is Axsome Therapeutics, Inc.

Did this study involve medication?

Yes. The study involved medication, including Solriamfetol 300 mg and Placebo.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies